Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Rifaximin in SIBO Patients with Abdominal Bloating
NCT06772064Recruiting
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of rifaximin in small intestinal bacterial overgrowth (SIBO) (2 arms). Primary endpoint: Negative conversion rate of hydrogen and methane breath testing. Started Apr 2025; status: recruiting.
02
Drugs
rifaximin
03
Conditions
small intestinal bacterial overgrowth (SIBO)
Beyond the preview
Go deeper on NCT06772064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06772064.